Search Results - "Gradishar W"

Taxanes for the Treatment of Metastatic Breast Cancer.

Authors: Gradishar, W. J.¹

Source: Breast Cancer: Basic & Clinical Research. 2012, Issue 6, p159-171. 13p. 3 Charts.

Elevated incidence of fractures in women with invasive breast cancer.

Authors: Gradishar, W. McKoy, J. Rosen, S. et al.

Source: Osteoporosis International. Feb2016, Vol. 27 Issue 2, p499-507. 9p. 4 Charts.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Authors: Gradishar, W. J.¹

Source: Annals of Oncology. Oct2013, Vol. 24 Issue 10, p2492-2500. 9p.

Advances in endocrine therapy of metastatic breast cancer.

Authors: Gradishar, W. J. Morrow, M.

Source: British Journal of Surgery. Dec2002, Vol. 89 Issue 12, p1489-1492. 4p.

Clinical review. Recent developments: breast cancer.

Authors: Morrow M Gradishar W

Source: BMJ: British Medical Journal (International Edition). 2/16/2002, Vol. 324 Issue 7334, p410-414. 5p.

U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer.

Authors: Nunes, A. P. Liang, C. Gradishar, W. J. et al.

Source: Current Oncology. Apr2019, Vol. 26 Issue 2, pe180-e187. 8p. 1 Diagram, 3 Charts, 1 Graph.

High-dose chemotherapy and breast cancer.

Authors: Gradishar, William J. Gradishar, W J

Source: JAMA: Journal of the American Medical Association. 10/13/99, Vol. 282 Issue 14, p1378-1380. 3p.

A Retrospective Analysis of nab-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors.

Authors: O'Shaughnessy, J. Gradishar, W. Bhar, P. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p352-353. 2p.

Possible role for cancer stem cells: results from a pilot neoadjuvant trial of HER-2 positive breast cancer patients treated with a combination of (Nab)-paclitaxel and lapatinib.

Authors: Siziopikou, K. P. Gradishar, W. J. Kaklamani, V. G.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p1461-1461. 1p.

The impact of BRCA testing on surgical treatment decisions for patients with breast cancer

Authors: Doll, K. Gradishar, W. Trosman, J. et al.

Source: Gynecologic Oncology. Mar2011 Supplement 1, Vol. 120, pS60-S61. 0p.

ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.

Authors: Malin, D Strekalova, E Petrovic, V et al.

Source: Oncogene. 11/5/2015, Vol. 34 Issue 45, p5626-5634. 9p. 5 Graphs.

High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.

Authors: Tallman, M S Rademaker, A W Jahnke, L et al.

Source: Bone Marrow Transplantation. 11/1/97, Vol. 20 Issue 9, p721. 9p.

EE417 Healthcare Resource Use and Costs of Care in HR+/HER2- Metastatic Breast Cancer: A Retrospective US Claims Data Study.

Authors: Collin, S Tse, J Shaikh, NF et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS134-S134. 1p.

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Authors: Costa, R. Carneiro, B. A. Wainwright, D. A. et al.

Source: Annals of Oncology. Jan2017, Vol. 28 Issue 1, p44-56. 13p. 2 Diagrams, 1 Chart.

The sequential use of endocrine treatment for advanced breast cancer: where are we?

Authors: Barrios, C. Forbes, J. F. Jonat, W. et al.

Source: Annals of Oncology. Jun2012, Vol. 23 Issue 6, p1378-1386. 9p.

324PSettings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review.

Authors: Rugo, H S Curigliano, G Cardoso, F et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103.

Authors: Miller, K. D. O'Neill, A. Dang, C. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p1605-1606. 2p.

Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors -- a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007).

Authors: Johnston, S. R. D. Chia, S. Kilburn, L. S. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p753-754. 2p.

PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy.

Authors: Liu, M. C. Pitcher, B. N. Mardis, E. R. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p585-586. 2p.

Validation of the Breast Cancer-specific Graded Prognostic Assessment (GPA) for Patients With Breast Cancer With Brain Metastases

Authors: Kalakota, K. Helenowski, I. Schumacher, A. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2012 Supplement, Vol. 84, pS117-S118. 0p.